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Recently Pascual and colleagues have contributed a study about the identity of cells that initiate metastasis (Pascual et al., 2017\[[@R22]\]). They identified a cell type in human oral carcinomas with the following properties: (1) slow-cycling, (2) CD44-bright, (3) low expression of mesenchymal genes, (4) ability to initiate metastasis in mouse models and (5) high expression of the fatty acid receptor CD36. CD36 is a membrane protein on the surface of many mammalian cells that imports fatty acids (Yang et al., 2018\[[@R34]\]; Umbarawan et al., 2018\[[@R31]\]; Son et al., 2018\[[@R28]\]). CD36 has been shown to be critical for supply with fatty acids and for maintenance of energy metabolism under numerous conditions (Wen et al, 2017\[[@R33]\]; Chen et al, 2016\[[@R5]\]; Nakatani et al., 2015\[[@R21]\]; le Foll et al., 2015\[[@R15]\], 2013\[[@R14]\]). In their recent study Pascual et al. report that neutralizing antibodies against CD36 reduce the formation of metastasis in orthotopic mouse models of oral cancer (Pascual et al., 2017\[[@R22]\]). A further finding of this study is that NOD scid gamma mice developed larger lymph node metastases in a CD36 dependent manner, when the mice received a high-fat diet. Moreover, the authors report that CD36 positive cells are metastasis initiating and are characterized by a lipid metabolism signature (Pascual et al., 2017\[[@R22]\]). Based on publicly available data, high expression of CD36 was associated with poor disease-free survival in breast, lung and urinary bladder cancer (Pascual et al., 2017\[[@R22]\]).

In the past decade much progress has been made in understanding the principles that control formation of metastases (McGranahan et al, 2017\[[@R20]\]; Lambert et al., 2017\[[@R13]\]; Adawy, 2017\[[@R1]\]; Marchan, 2012\[[@R18]\]; Cadenas, 2012\[[@R2]\]; Mantovani et al., 2017\[[@R17]\]; Zhan et al, 2017\[[@R35]\]). It is generally accepted that the cellular and humoral immune system play an important role in preventing metastasis (Schmidt et al., 2018\[[@R25]\], 2012\[[@R24]\], 2008\[[@R23]\]; Godoy et al., 2014\[[@R6]\]; Heimes et a., 2017\[[@R8]\]\[[@R9]\]; Sicking et al., 2014\[[@R26]\]).

In many tumor types high expression of proliferation associated genes has been shown to lead to an increased risk of metastasis (Schmidt et al., 2008\[[@R23]\]; Siggelkow et al., 2012\[[@R27]\]; Jabs et al., 2017\[[@R11]\]; Wei et al,, 2017\[[@R32]\]; Knaack, et al, 2018\[[@R12]\]). Moreover, high expression of antioxidative factors (Cadenas et al, 2010\[[@R3]\]), disturbed expression of genes involved in the control of circadian rhythm (Cadenas et al., 2014\[[@R4]\]) and actin binding proteins (Stock et al., 2015\[[@R30]\]) are associated with shorter metastasis-free interval.Different principles have been shown to control breast cancer metastasis that occurs within the first three years after the primary tumor or later (Hellwig et al., 2016\[[@R10]\]; Hammad et al., 2016\[[@R7]\]). Finally, factors involved in glycerophospholipid metabolism have been shown to influence the capacity of tumor cells to migrate, attach to surfaces and to metastasize (Stewart et al., 2012\[[@R29]\]; Lesjak et al., 2014\[[@R16]\]; Marchan et al., 2017\[[@R19]\]).

In conclusion, Pascual and colleagues bring forward an interesting concept that metastasis-initiating tumor cells rely on dietary lipids in a CD36 dependent manner. It remains to be shown, whether CD36 is a promising target for anti-cancer therapy.
